Related Experiment Videos
Fibronectin as target for tumor therapy.
Manuela Kaspar1, Luciano Zardi, Dario Neri
1Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland.
International Journal of Cancer
|December 29, 2005
Summary
Cancer progression involves extracellular matrix (ECM) remodeling. Fibronectin (FN) is a key target for developing novel cancer therapies and imaging agents due to its role in tumor growth and its unique tumor-associated isoforms.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Cancer progression involves significant extracellular matrix (ECM) remodeling.
- Fibronectin (FN), an abundant glycoprotein, is crucial for ECM function and cell interactions.
- Tumor-associated FN isoforms present unique targets for cancer therapies.
Purpose of the Study:
- To review the properties of fibronectin (FN).
- To focus on therapeutic strategies targeting FN in cancer.
- To discuss the use of FN fragments for tumor growth inhibition.
Main Methods:
- Review of existing literature on fibronectin.
- Analysis of preclinical and clinical studies targeting FN.
- Examination of therapeutic strategies utilizing FN fragments.
Main Results:
- Fibronectin plays a central role in ECM remodeling during cancer.
- Targeting FN interactions with cell surface receptors is a viable therapeutic approach.
- Tumor-specific FN isoforms enable targeted delivery of therapeutic and imaging agents.
Conclusions:
- Fibronectin is a promising target for developing novel cancer therapies.
- Targeted interventions based on FN, including inhibitory molecules and ligand-based strategies, are under development.
- FN fragments can be utilized to inhibit tumor growth.